Mino Pharma: Plans to raise no more than 2.109 billion yuan through private placement for high-activity preparations and high-end R&D for poorly soluble drugs projects
Meinuo Hua plans to raise up to 2.109 billion yuan through a private placement of shares. The funds will be allocated to projects including a global industrial base for high-end oral solid preparations and complex injections, as well as an R&D initiative for high-activity and poorly soluble drugs. A portion of the capital will also be used to supplement working capital. AI
IMPACT This funding will support R&D in advanced drug formulations, potentially leading to new therapeutic options.